Editorial: Cancer Treatment and Early Detection Targeting HER Receptors.
作者信息
Cai Xiaoqing, Zhang Libing, Chen Shengxi
机构信息
School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou, China.
Tianjin Key Laboratory of Molecular Optoelectronic, Department of Chemistry, Tianjin University, Tianjin, China.
出版信息
Front Mol Biosci. 2022 Jun 15;9:940055. doi: 10.3389/fmolb.2022.940055. eCollection 2022.
Abstract
摘要
相似文献
1
Editorial: Cancer Treatment and Early Detection Targeting HER Receptors.社论：针对HER受体的癌症治疗与早期检测
Front Mol Biosci. 2022 Jun 15;9:940055. doi: 10.3389/fmolb.2022.940055. eCollection 2022.
2
Editorial: Cancer treatment and early detection targeting HER receptors, Volume II.社论：靶向HER受体的癌症治疗与早期检测，第二卷
Front Mol Biosci. 2023 Jun 22;10:1229765. doi: 10.3389/fmolb.2023.1229765. eCollection 2023.
3
Neuropeptide bombesin receptor activation stimulates growth of lung cancer cells through HER3 with a MAPK-dependent mechanism.神经肽蛙皮素受体的激活通过 HER3 以 MAPK 依赖的机制刺激肺癌细胞的生长。
Biochim Biophys Acta Mol Cell Res. 2020 Apr;1867(4):118625. doi: 10.1016/j.bbamcr.2019.118625. Epub 2019 Dec 17.
4
Evaluation of the antitumor effects and mechanisms of PF00299804, a pan-HER inhibitor, alone or in combination with chemotherapy or targeted agents in gastric cancer.PF00299804（一种泛 HER 抑制剂）单药或联合化疗或靶向药物治疗胃癌的抗肿瘤作用及机制评价。
Mol Cancer Ther. 2012 Feb;11(2):439-51. doi: 10.1158/1535-7163.MCT-11-0494. Epub 2011 Dec 1.
5
Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy.通过基于抗体的疗法双重靶向HER家族受体克服西妥昔单抗的获得性耐药
Mol Cancer. 2014 Oct 24;13:242. doi: 10.1186/1476-4598-13-242.
6
7
Model-based analysis of HER activation in cells co-expressing EGFR, HER2 and HER3.基于模型的分析在共表达 EGFR、HER2 和 HER3 的细胞中 HER 激活。
PLoS Comput Biol. 2013;9(8):e1003201. doi: 10.1371/journal.pcbi.1003201. Epub 2013 Aug 22.
8
Evaluation of the prognostic significance of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) validation study.HER家族mRNA表达在高危早期乳腺癌中的预后意义评估：一项希腊合作肿瘤学组（HeCOG）验证研究
J Transl Med. 2015 May 29;13:171. doi: 10.1186/s12967-015-0530-0.
9
Overexpression and gene amplification of EGFR, HER2, and HER3 in biliary tract carcinomas, and the possibility for therapy with the HER2-targeting antibody pertuzumab.在胆管癌中 EGFR、HER2 和 HER3 的过表达和基因扩增，以及使用 HER2 靶向抗体 pertuzumab 进行治疗的可能性。
J Gastroenterol. 2015 Apr;50(4):467-79. doi: 10.1007/s00535-014-0984-5. Epub 2014 Aug 12.
10
Comparative study on overexpression of HER2/neu and HER3 in gastric cancer.胃癌中HER2/neu和HER3过表达的比较研究
World J Surg. 2009 Oct;33(10):2112-8. doi: 10.1007/s00268-009-0142-z.
引用本文的文献
1
Editorial: EGFR-TKIs for lung cancer treatment: development, application, and side effects.社论：用于肺癌治疗的表皮生长因子受体酪氨酸激酶抑制剂：研发、应用及副作用
Front Oncol. 2025 May 22;15:1617788. doi: 10.3389/fonc.2025.1617788. eCollection 2025.
2
Editorial: New strategies for reversing cancer therapy resistance.社论：逆转癌症治疗耐药性的新策略
Front Pharmacol. 2024 Apr 18;15:1411519. doi: 10.3389/fphar.2024.1411519. eCollection 2024.
3
Editorial: Cancer treatment and early detection targeting HER receptors, Volume II.社论：靶向HER受体的癌症治疗与早期检测，第二卷
Front Mol Biosci. 2023 Jun 22;10:1229765. doi: 10.3389/fmolb.2023.1229765. eCollection 2023.
本文引用的文献
1
A Review of HER4 (ErbB4) Kinase, Its Impact on Cancer, and Its Inhibitors.HER4（ErbB4）激酶综述：其对癌症的影响及其抑制剂。
Molecules. 2021 Dec 5;26(23):7376. doi: 10.3390/molecules26237376.
2
DNA-affibody nanoparticles for inhibiting breast cancer cells overexpressing HER2.用于抑制过表达HER2的乳腺癌细胞的DNA亲和体纳米颗粒。
Chem Commun (Camb). 2017 Jan 3;53(3):573-576. doi: 10.1039/c6cc08495h.
3
EGFR-expression in primary urinary bladder cancer and corresponding metastases and the relation to HER2-expression. On the possibility to target these receptors with radionuclides.原发性膀胱癌及其相应转移灶中 EGFR 的表达及与 HER2 表达的关系。探讨用放射性核素来靶向这些受体的可能性。
Radiol Oncol. 2015 Mar 3;49(1):50-8. doi: 10.2478/raon-2014-0015. eCollection 2015 Mar.
4
The epidermal growth factor-like domain of CD93 is a potent angiogenic factor.CD93 的表皮生长因子样结构域是一种有效的血管生成因子。
PLoS One. 2012;7(12):e51647. doi: 10.1371/journal.pone.0051647. Epub 2012 Dec 18.
5
Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients.采用标准化方法评估 HER2 基因扩增作为浸润性膀胱癌治疗的潜在靶点：1005 例患者的结果。
Ann Oncol. 2010 Apr;21(4):815-819. doi: 10.1093/annonc/mdp488. Epub 2009 Nov 4.
Zotero 插件